Sveriges mest populära poddar

Season 2, Episode 14

19 min•8 april 2021

In this week’s episode, we discuss recent studies providing new insights on the use of minimal residual disease measurements to guide treatment in patients with high-risk ALL; the increasing risk of venous thromboembolism among patients with cancer; and the use of tocilizumab in the prophylaxis of acute graft versus host disease.

Fler avsnitt av Blood Podcast

Cost-Effectiveness of Current SCD Treatments and Potential Therapeutic Targets for Fetal Hemoglobinopathies

13 aug.•33 min

HLH-like toxicities after CAR-T and Structure-Function Relationships of FNAIT

6 aug.•17 min

FLT3-ITD microclones in AML and Results from the RESET-PV trial

30 juli•14 min

Initial CHORUS data on HHT and ASH HematOmics Program

23 juli•26 min

IV Iron during Acute Infection and Revisiting iTTP Refractoriness

16 juli•17 min

A Pediatric ITP Risk Model and Targeting CD2 with CAR T-cell therapies

9 juli•18 min

IV Iron Risks and Low-Dose AML Gains

2 juli•25 min

Orca-T for GVHD–free survival and Understanding VEXAS anemia

25 juni•23 min

Treating AML, Before and After Relapse

18 juni•16 min

Future Directions in Relapsed and Refractory Large B-cell Lymphoma

11 juni•25 min

Blood Podcast med American Society of Hematology finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.